Earlier access to a bispecific immunotherapy could reshape multiple myeloma sequencing and improve survival for patients who have exhausted standard options.
The MajesTEC‑9 Phase III data provide the most compelling evidence to date that a bispecific antibody can outperform conventional chemo‑immunotherapy in the second‑line setting for relapsed/refractory multiple myeloma (RRMM). By targeting BCMA on malignant plasma cells and CD3 on T cells, teclistamab harnesses the patient’s own immune system to achieve deep, durable responses. The trial’s hazard ratios—71 % lower risk of disease progression and a 40 % reduction in death—translate into meaningful extensions of progression‑free and overall survival for a cohort that is largely refractory to anti‑CD38 monoclonal antibodies and lenalidomide.
From a commercial perspective, the EMA Type II variation could unlock a sizable market segment that currently relies on combination regimens such as PVd or Kd. Bispecific antibodies have already secured a foothold in later‑line myeloma therapy, but positioning teclistamab earlier may pressure competitors to accelerate their own immunotherapy pipelines. Payers will scrutinize the cost‑effectiveness of a single‑agent biologic versus multi‑drug combos, yet the demonstrated survival advantage and manageable safety profile could justify premium pricing and broader reimbursement. This could also influence formulary decisions across Europe.
Looking ahead, Johnson & Johnson plans to present the full MajesTEC‑9 dataset at a major oncology congress and to pursue parallel submissions in the United States and other jurisdictions. If approved, clinicians could incorporate teclistamab into treatment algorithms soon after frontline therapy, potentially redefining the standard of care for RRMM. Earlier bispecific use also raises questions about optimal sequencing with emerging CAR‑T and antibody‑drug conjugates, suggesting a new era of personalized immunotherapy strategies that prioritize depth of response and quality of life.
Comments
Want to join the conversation?
Loading comments...